Dr Teresa Nicoletti is a lawyer and PhD-qualified scientist, and Partner at Mills Oakley, leading the firm’s Health and Life Sciences practice. A recognised authority on therapeutic goods regulation, she advises LLS on compliance, regulatory pathways, and ethical governance across the complementary and prescription medicine landscape.

Dr Ross Walker is a practising cardiologist with more than 45 years of clinical experience and a global reputation in preventative cardiology. As a medical advisor to Longevity Life Sciences, he brings deep expertise in cardiovascular health, and translational medicine to support LLS’s mission of extending human healthspan.

​

Professor Katie Allen is a physician-scientist and international leader in allergy and public health research. Her work has shaped national and global clinical guidelines and health policy. As an advisor to LLS, she contributes expertise in clinical research translation, public health strategy, and the integration of science into policy and practice.

George Papadopoulos is a health economist and strategic market access specialist with over 25 years of experience across the global pharmaceutical industry. He provides LLS with expertise in reimbursement, and health technology assessment, guiding evidence-to-access strategies that ensure clinical innovation translates responsibly to market.

Associate Professor Sophie Stocker is a clinical pharmacologist and academic at the University of Sydney’s School of Pharmacy. Her research focuses on precision dosing and variability in medicine response. At LLS, she provides scientific oversight and guidance on clinical trial design, pharmacology, and translational research excellence.​​

Dr Brad McEwen is a nutrition scientist and naturopath with over 20 years of clinical and research experience. His work examines how nutrition and lifestyle interventions support healthy ageing and disease prevention. As an advisor to LLS, he provides expertise in nutritional biochemistry and evidence-based approaches to research and product development.

Kathryn Williams is a global regulatory and market access strategist with extensive experience guiding biotech companies through complex FDA, EMA, MHRA, and TGA pathways. She supports LLS in shaping regulatory foresight and global expansion strategy, ensuring science-driven innovation is aligned with international standards and patient access priorities.